Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?

Literature DB >> 28798034

¹⁸F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?

Sally F Barrington¹, Peter W M Johnson².

Abstract

PET/CT using 18F-FDG is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy. Attempts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in patients treated with rituximab and chemotherapy. Trials are under way to determine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. More recently, PET has been reported to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective trials to test PET-guided therapy in this disease are anticipated.

Entities: Chemical

Keywords: lymphoma; positron emission tomography; precision medicine

Mesh：

Substances：
Fluorodeoxyglucose F18

Year: 2017 PMID： 28798034 PMCID： PMC5632732 DOI： 10.2967/jnumed.116.181347

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

25 in total

1. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Authors: Mark Hertzberg; Maher K Gandhi; Judith Trotman; Belinda Butcher; John Taper; Amanda Johnston; Devinder Gill; Shir-Jing Ho; Gavin Cull; Keith Fay; Geoff Chong; Andrew Grigg; Ian D Lewis; Sam Milliken; William Renwick; Uwe Hahn; Robin Filshie; George Kannourakis; Anne-Marie Watson; Pauline Warburton; Andrew Wirth; John F Seymour; Michael S Hofman; Rodney J Hicks
Journal: Haematologica Date: 2016-11-10 Impact factor: 9.941

2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544

3. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors: Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544

4. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP_escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Authors: Peter Borchmann; Heinz Haverkamp; Andreas Lohri; Ulrich Mey; Stefanie Kreissl; Richard Greil; Jana Markova; Michaela Feuring-Buske; Julia Meissner; Ulrich Dührsen; Helmut Ostermann; Ulrich Keller; Georg Maschmeyer; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Andreas Engert
Journal: Lancet Oncol Date: 2017-02-22 Impact factor: 41.316

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

6. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

Authors: Judith Trotman; Stefano Luminari; Sami Boussetta; Annibale Versari; Jehan Dupuis; Christelle Tychyj; Luigi Marcheselli; Alina Berriolo-Riedinger; Antonella Franceschetto; Anne Julian; Fabien Ricard; Luca Guerra; Corinne Haioun; Irene Biasoli; Hervé Tilly; Massimo Federico; Gilles Salles; Michel Meignan
Journal: Lancet Haematol Date: 2014-09-17 Impact factor: 18.959

7. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors: Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal: N Engl J Med Date: 2013-04-11 Impact factor: 91.245

8. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors: John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal: N Engl J Med Date: 2015-04-23 Impact factor: 91.245

9. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Authors: Sally F Barrington; Amy A Kirkwood; Antonella Franceschetto; Michael J Fulham; Thomas H Roberts; Helén Almquist; Eva Brun; Karin Hjorthaug; Zaid N Viney; Lucy C Pike; Massimo Federico; Stefano Luminari; John Radford; Judith Trotman; Alexander Fosså; Leanne Berkahn; Daniel Molin; Francesco D'Amore; Donald A Sinclair; Paul Smith; Michael J O'Doherty; Lindsey Stevens; Peter W Johnson
Journal: Blood Date: 2016-01-08 Impact factor: 22.113

Review 10. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Authors: Peter W M Johnson
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

12 in total

1. ¹⁸F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Authors: Kirstin A Zettlitz; Richard Tavaré; Wen-Ting K Tsai; Reiko E Yamada; Noel S Ha; Jeffrey Collins; R Michael van Dam; John M Timmerman; Anna M Wu
Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-19 Impact factor: 9.236

2. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors: Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal: Cochrane Database Syst Rev Date: 2019-09-16

Review 3. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.

Authors: Kathleen M McCarten; Helen R Nadel; Barry L Shulkin; Steve Y Cho
Journal: Pediatr Radiol Date: 2019-10-16

4. Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.

Authors: Jasmin Mettler; Horst Müller; Conrad-Amadeus Voltin; Christian Baues; Bernd Klaeser; Alden Moccia; Peter Borchmann; Andreas Engert; Georg Kuhnert; Alexander E Drzezga; Markus Dietlein; Carsten Kobe
Journal: J Nucl Med Date: 2018-06-07 Impact factor: 10.057

5. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

6. Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.

Authors: Dominik Berzaczy; Alexander R Haug; Markus Raderer; Barbara Kiesewetter; Gundula Berzaczy; Michael Weber; Marius E Mayerhoefer
Journal: PLoS One Date: 2019-03-08 Impact factor: 3.240

Review 7. Biomarker selection and imaging design in cancer: A link with biochemical pathways for imminent engineering.

Authors: Joham Surfraz Ali; Noor Ul Ain; Sania Naz; Muhammad Zia
Journal: Heliyon Date: 2020-02-03

8. The effect of hypothyroidism on referential background metabolic activity on ¹⁸F-FDG PET/CT.

Authors: Pei Yang; Qiuping Fan; Huawei Cai; Rong Tian; Minggang Su
Journal: Quant Imaging Med Surg Date: 2021-08

9. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma.

Authors: Gerben J C Zwezerijnen; Jakoba J Eertink; Coreline N Burggraaff; Sanne E Wiegers; Ekhlas A I N Shaban; Simone Pieplenbosch; Daniela E Oprea-Lager; Pieternella J Lugtenburg; Otto S Hoekstra; Henrica C W de Vet; Josee M Zijlstra; Ronald Boellaard
Journal: J Nucl Med Date: 2021-03-05 Impact factor: 11.082

10. Metabolic tumor volume changes assessed by interval ¹⁸fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma.

Authors: Luis F Oñate-Ocaña; Violeta Cortés; Rodrigo Castillo-Llanos; Andrea Terrazas; Osvaldo Garcia-Perez; Quetzalli Pitalúa-Cortes; Mayra Ponce; Alfonso Dueñas-Gonzalez; Myrna Candelaria
Journal: Oncol Lett Date: 2018-05-25 Impact factor: 2.967